Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3

Authors: Byung-Hak Kim, Jun-Goo Jee, Chang-Hong Yin, Claudio Sandoval, Somasundaram Jayabose, Daisuke Kitamura, Erika A Bach, Gyeong-Hun Baeg

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

Human or animals lacking either JAK3 or the common gamma chain (γc) expression display severe combined immunodeficiency disease, indicating the crucial role of JAK3 in T-cell development and the homeostasis of the immune system. JAK3 has also been suggested to contribute to the pathogenesis of tumorigenesis. Recent studies identified activating JAK3 mutations in patients with various hematopoietic malignancies, including acute megakaryoblastic leukemia. Importantly, functional analyses of some of those JAK3 mutations have been shown to cause lethal hematopoietic malignancies in animal models. These observations make JAK3 an ideal therapeutic target for the treatment of various human diseases. To identify novel small molecule inhibitors of JAK3, we performed structure-based virtual screen using the 3D structure of JAK3 kinase domain and the NCI diversity set of compounds.

Results

We identified NSC114792 as a lead compound. This compound directly blocked the catalytic activity of JAK3 but not that of other JAK family members in vitro. In addition, treatment of 32D/IL-2Rβ cells with the compound led to a block in IL-2-dependent activation of JAK3/STAT5 but not IL-3-dependent activation of JAK2/STAT5. Consistent with the specificity of NSC114792 for JAK3, it selectively inhibited persistently-activated JAK3, but failed to affect the activity of other JAK family members and other oncogenic kinases in various cancer cell lines. Finally, we showed that NSC114792 decreases cell viability by inducing apoptosis through down-regulating anti-apoptotic gene expression only in cancer cells harboring persistently-active JAK3.

Conclusions

NSC114792 is a lead compound that selectively inhibits JAK3 activity. Therefore, our study suggests that this small molecule inhibitor of JAK3 can be used as a starting point to develop a new class of drugs targeting JAK3 activity, and may have therapeutic potential in various diseases that are caused by aberrant JAK3 activity.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Rochman Y, Spolski R, Leonard WJ: New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol. 2009, 9: 480-490. 10.1038/nri2580PubMedCentralCrossRefPubMed
4.
Malaviya R, Uckun FM: Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions. Biochem Biophys Res Commun. 1999, 257: 807-813. 10.1006/bbrc.1999.0513CrossRefPubMed
5.
Papageorgiou AC, Wikman LE: Is JAK3 a new drug target for immunomodulation-based therapies?. Trends Pharmacol Sci. 2004, 25: 558-562. 10.1016/j.tips.2004.09.008CrossRefPubMed
6.
O'Shea JJ, Pesu M, Borie DC, Changelian PS: A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov. 2004, 3: 555-564. 10.1038/nrd1441CrossRefPubMed
7.
Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, Boggon TJ, Heinrich MC, Deininger MW, Polakiewicz RD, Gilliland DG, Druker BJ: Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 2006, 10: 65-75. 10.1016/j.ccr.2006.06.002CrossRefPubMed
8.
Kiyoi H, Yamaji S, Kojima S, Naoe T: JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia. 2007, 21: 574-576. 10.1038/sj.leu.2404527CrossRefPubMed
9.
Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C, Villeval JL, Reinhardt D, Landman-Parker J, Michaux L, Dastugue N, Baruchel A, Vainchenker W, Bourquin JP, Penard-Lacronique V, Bernard OA: Activating mutations in human acute megakaryoblastic leukemia. Blood. 2008, 112: 4220-4226. 10.1182/blood-2008-01-136366CrossRefPubMed
10.
Sato T, Toki T, Kanezaki R, Xu G, Terui K, Kanegane H, Miura M, Adachi S, Migita M, Morinaga S, Nakano T, Endo M, Kojima S, Kiyoi H, Mano H, Ito E: Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome. Br J Haematol. 2008, 141: 681-688. 10.1111/j.1365-2141.2008.07081.xCrossRefPubMed
11.
Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, Tasian SK, Loh ML, Su X, Liu W, Devidas M, Atlas SR, Chen IM, Clifford RJ, Gerhard DS, Carroll WL, Reaman GH, Smith M, Downing JR, Hunger SP, Willman CL: JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2009, 106: 9414-9418. 10.1073/pnas.0811761106PubMedCentralCrossRefPubMed
12.
Cornejo MG, Kharas MG, Werneck MB, Le Bras S, Moore SA, Ball B, Beylot-Barry M, Rodig SJ, Aster JC, Lee BH, Cantor H, Merlio JP, Gilliland DG, Mercher T: Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood. 2009, 113: 2746-2754. 10.1182/blood-2008-06-164368PubMedCentralCrossRefPubMed
13.
Yared MA, Khoury JD, Medeiros LJ, Rassidakis GZ, Lai R: Activation status of the JAK/STAT3 pathway in mantle cell lymphoma. Arch Pathol Lab Med. 2005, 129: 990-996.PubMed
14.
Gee K, Kozlowski M, Kryworuchko M, Diaz-Mitoma F, Kumar A: Differential effect of IL-4 and IL-13 on CD44 expression in the Burkitt's lymphoma B cell line BL30/B95-8 and in Epstein-Barr virus (EBV) transformed human B cells: loss of IL-13 receptors on Burkitt's lymphoma B cells. Cell Immunol. 2001, 211: 131-142. 10.1006/cimm.2001.1829CrossRefPubMed
15.
Lai R, Rassidakis GZ, Lin Q, Atwell C, Medeiros LJ, Amin HM: Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma. Hum Pathol. 2005, 36: 939-944. 10.1016/j.humpath.2005.07.011CrossRefPubMed
16.
Amin HM, Medeiros LJ, Ma Y, Fereyzaki M, Das P, Leventaki V, Rassidakis GZ, O'Conner SL, McDonell TJ, Lai R: Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene. 2003, 22: 5399-5407. 10.1038/sj.onc.1206849CrossRefPubMed
17.
Qui L, Lai R, Lin Q, Lau E, Thomazy DM, Calame D, Ford RJ, Kwak LW, Kirken RA, AMin HM: Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large cell lymphoma. Blood. 2006, 108: 2407-2415. 10.1182/blood-2006-04-020305CrossRef
18.
Nakayama J, Yamamoto M, Hayashi K, Satoh H, Bundo K, Kubo M, Goitsuka R, Farrar MA, Kitamura D: BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3. Blood. 2009, 113: 1483-1492. 10.1182/blood-2008-07-166355PubMedCentralCrossRefPubMed
19.
Jumaa H, Bossaller L, Portugal K, Storch B, Lotz M, Flemming A, Schrappe M, Postila V, Riikonen P, Pelkonen J, Niemeyer CM, Reth M: Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia. Nature. 2003, 423: 452-456. 10.1038/nature01608CrossRefPubMed
20.
Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K, Hamilton SR, Amin HM: Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol. 2005, 167: 969-980.PubMedCentralCrossRefPubMed
21.
Jeong EG, Kim MS, Nam HK, Min CK, Lee S, Chung YJ, Yoo NJ, Lee SH: Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res. 2008, 14: 3716-3721. 10.1158/1078-0432.CCR-07-4839CrossRefPubMed
22.
Abramovich C, Shulman LM, Ratovitski E, Harroch S, Tovey M, Eid P, Revel M: Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-alpha and IFN-beta. EMBO J. 1994, 13: 5871-5877.PubMedCentralPubMed
23.
Choi YL, Kaneda R, Wada T, Fujiwara S, Soda M, Watanabe H, Kurashina K, Hatanaka H, Enomoto M, Takada S, Yamashita Y, Mano H: Identification of a constitutively active mutant of JAK3 by retroviral expression screening. Leuk Res. 2007, 31: 203-209. 10.1016/j.leukres.2006.05.006CrossRefPubMed
24.
Silvennoinen O, Witthuhn BA, Quelle FW, Cleveland JL, Yi T, Ihle JN: Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc Natl Acad Sci USA. 1993, 90: 8429-8433. 10.1073/pnas.90.18.8429PubMedCentralCrossRefPubMed
25.
Chilton BS, Hewetson A: Prolactin and growth hormone signaling. Curr Top Dev Biol. 2005, 68: 1-23. 10.1016/S0070-2153(05)68001-5CrossRefPubMed
26.
Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ: Therapeutic targeting of Janus kinases. Immunol Rev. 2008, 223: 132-142. 10.1111/j.1600-065X.2008.00644.xPubMedCentralCrossRefPubMed
27.
Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O'Shea JJ: Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev. 2005, 203: 127-142. 10.1111/j.0105-2896.2005.00220.xCrossRefPubMed
28.
Kirken RA, Rui H, Malabarba MG, Farrar WL: Identification of interleukin-2 receptor-associated tyrosine kinase p116 as novel leukocyte-specific Janus kinase. J Biol Chem. 1994, 269: 19136-19141.PubMed
29.
Cortes JR, Perez-G M, Rivas MD, Zamorano J: Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3. J Immunol. 2007, 179: 3881-3887.CrossRefPubMed
30.
31.
Parsons SJ, Parsons JT: Src family kinases, key regulators of signal transduction. Oncogene. 2004, 23: 7906-7909. 10.1038/sj.onc.1208160CrossRefPubMed
32.
Bharti AC, Donato N, Aggarwal BB: Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol. 2003, 171: 3863-3871.CrossRefPubMed
33.
Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM: Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003, 63: 1270-1279.PubMed
34.
Lipka DB, Hoffmann LS, Heidel F, Markova B, Blum MC, Breitenbuecher F, Kasper S, Kindler T, Levine RL, Huber C, Fischer T: LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol Cancer Ther. 2008, 7: 1176-1184. 10.1158/1535-7163.MCT-07-2215CrossRefPubMed
35.
Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S, Song JH, Yin D, Toh M, Xie WD, Said JW, Koeffler HP: Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res. 2009, 69: 5876-5884. 10.1158/0008-5472.CAN-09-0536CrossRefPubMed
36.
Kim BH, Oh SR, Yin CH, Lee S, Kim EA, Kim MS, Sandoval C, Jayabose S, Bach EA, Lee HK, Baeg GH: MS-1020 is a novel small molecule that selectively inhibits JAK3 activity. Br J Haematol. 2010, 148: 132-143. 10.1111/j.1365-2141.2009.07925.xPubMedCentralCrossRefPubMed
37.
Decker P, Isenberg D, Muller S: Inhibition of caspase-3-mediated poly(ADP-ribose) polymerase (PARP) apoptotic cleavage by human PARP autoantibodies and effect on cells undergoing apoptosis. J Biol Chem. 2000, 275: 9043-9046. 10.1074/jbc.275.12.9043CrossRefPubMed
38.
Nosaka T, van Deursen JM, Tripp RA, Thierfelder WE, Witthuhn BA, McMickle AP, Doherty PC, Grosveld GC, Ihle JN: Defective lymphoid development in mice lacking Jak3. Science. 1995, 270: 800-2. 10.1126/science.270.5237.800CrossRefPubMed
39.
Suzuki K, Nakajima H, Saito Y, Saito T, Leonard WJ, Iwamoto I: Janus kinase 3 (Jak3) is essential for common cytokine receptor gamma chain (gamma(c))-dependent signaling: comparative analysis of gamma(c), Jak3, and gamma(c) and Jak3 double-deficient mice. Int Immunol. 2000, 12: 123-132. 10.1093/intimm/12.2.123CrossRefPubMed
40.
Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH, McCurdy SP, Kudlacz EM, Conklyn MJ, Elliott EA, Koslov ER, Fisher MB, Strelevitz TJ, Yoon K, Whipple DA, Sun J, Munchhof MJ, Doty JL, Casavant JM, Blumenkopf TA, Hines M, Brown MF, Lillie BM, Subramanyam C, Shang-Poa C, Milici AJ, Beckius GE, Moyer JD, Su C, Woodworth TG, Gaweco AS, Beals CR, Littman BH, Fisher DA, Smith JF, Zagouras P, Magna HA, Saltarelli MJ, Johnson KS, Nelms LF, Des Etages SG, Hayes LS, Kawabata TT, Finco-Kent D, Baker DL, Larson M, Si MS, Paniagua R, Higgins J, Holm B, Reitz B, Zhou YJ, Morris RE, O'Shea JJ, Borie DC: Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003, 302: 875-878. 10.1126/science.1087061CrossRefPubMed
41.
Stepkowski SM, Erwin-Cohen RA, Behbod F, Wang ME, Qu X, Tejpal N, Nagy ZS, Kahan BD, Kirken RA: Selective inhibitor of Janus tyrosine kinase 3, PNU15 prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood. 6804, 99: 680-689. 10.1182/blood.V99.2.680.CrossRef
42.
Deuse T, Velotta JB, Hoyt G, Govaert JA, Taylor V, Masuda E, Herlaar E, Park G, Carroll D, Pelletier MP, Robbins RC, Schrepfer S: Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection. Transplantation. 2008, 85: 885-892. 10.1097/TP.0b013e318166acc4CrossRefPubMed
43.
Pozzan A: Molecular descriptors and methods for ligand based virtual high throughput screening in drug discovery. Curr Pharm Des. 2006, 12: 2099-2110. 10.2174/138161206777585247CrossRefPubMed
44.
Goodsell DS, Morris GM, Olson AJ: Automated docking of flexible ligands: applications of AutoDock. J Mol Recognit. 1996, 9: 1-5. 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6CrossRefPubMed
45.
Boggon TJ, Li Y, Manley PW, Eck MJ: Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood. 2005, 106: 996-1002. 10.1182/blood-2005-02-0707PubMedCentralCrossRefPubMed
46.
Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, Klebe G, Baker NA: PDB2PQR: Expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res. 2007, 35: W522-W525. 10.1093/nar/gkm276PubMedCentralCrossRefPubMed
47.
Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM, Onufriev A, Simmerling C, Wang B, Woods RJ: The Amber biomolecular simulation programs. J Comput Chem. 2005, 26: 1668-1688. 10.1002/jcc.20290PubMedCentralCrossRefPubMed
48.
Clevenger CV, Altmann SW, Prystowsky MB: Requirement of nuclear prolactin for interleukin-2--stimulated proliferation of T lymphocytes. Science. 1991, 253: 77-79. 10.1126/science.2063207CrossRefPubMed
49.
Zamorano J, Wang HY, Wang R, Shi Y, Longmore GD, Keegan AD: Regulation of cell growth by IL-2: role of STAT5 in protection from apoptosis but not in cell cycle progression. J Immunol. 1998, 160: 3502-3512.PubMed
50.
Wu Z, Xue HH, Bernard J, Zeng R, Issakov D, Bollenbacher-Reilley J, Belyakov IM, Oh S, Berzofsky JA, Leonard WJ: The IL-15 receptor {alpha} chain cytoplasmic domain is critical for normal IL-15Ralpha function but is not required for trans-presentation. Blood. 2008, 112: 4411-4419. 10.1182/blood-2007-03-080697PubMedCentralCrossRefPubMed
Metadata
Title
NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3
Authors
Byung-Hak Kim
Jun-Goo Jee
Chang-Hong Yin
Claudio Sandoval
Somasundaram Jayabose
Daisuke Kitamura
Erika A Bach
Gyeong-Hun Baeg
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-36

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Research

NF-κB/STAT3/PI3K signaling crosstalk in iMycEμ B lymphoma

Short communication

Extracellular matrix rigidity modulates neuroblastoma cell differentiation and N-myc expression

Research

MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells

Research

Integrative analysis of DNA copy number and gene expression in metastatic oral squamous cell carcinoma identifies genes associated with poor survival

Research

The promoter for intestinal cell kinase is head-to-head with F-Box 9 and contains functional sites for TCF7L2 and FOXA factors

Research

TGFBI expression is associated with a better response to chemotherapy in NSCLC
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits